Health Catalyst files Form 144 to sell 18,804 shares
Health Catalyst, Inc. reports a proposed sale of 18,804 shares of Common Stock under Form 144.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Health Catalyst, Inc. reports a proposed sale of 18,804 shares of Common Stock under Form 144. The filing lists these as restricted stock associated with compensation, with the proposed sale date of 06/01/2026.
The excerpt also shows 26,970 shares sold in the prior three months and indicates 73,894,020 shares outstanding as of 06/01/2026.
Insights
Form 144 notifies the market of a planned sale of restricted shares by an insider/affiliate.
The filing lists 18,804 shares of restricted Common Stock proposed for sale on 06/01/2026; the method is labeled compensation. This is a regulatory notice required before certain sales by affiliates.
Timing and proceeds treatment are not specified in the excerpt. Subsequent Form 4 or a resale report would show actual sale completion and net proceeds.
The proposed sale size is small relative to shares outstanding.
The filing shows 18,804 shares proposed versus 73,894,020 shares outstanding as of 06/01/2026, indicating limited potential overhang from this single notice.
Past three‑month disposals of 26,970 shares are shown; watch for any Form 4s that confirm execution or method of sale.
Key Figures
Key Terms
Restricted Stock financial
Form 144 regulatory
Compensation financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Health Catalyst's (HCAT) Form 144 report show?
When does a Form 144 become relevant to market activity for HCAT?
AI-generated analysis. How Rhea-AI works. Not financial advice.